Annals of radiation therapy and oncology最新文献

{"title":"Dosimetric Comparison of 3-Dimensional Conformal Radiotherapy (3DCRT), Intensity Modulated Radiotherapy (IMRT) and Volumetric-Arc Radiotherapy (VMAT) in Cervical Cancer Treatment","authors":"Pritanjali S, R. K, A. R","doi":"10.25107/2577-8757-v4-id1022","DOIUrl":"https://doi.org/10.25107/2577-8757-v4-id1022","url":null,"abstract":"Background: Cervical cancer being the fourth most frequently diagnosed cancer, concurrent chemoradiation forms the mainstay of the treatment from stage IB3 to IVA. As we witnessed advancement in radiotherapy technologies, attempts had been taken to reduce the dose to the OARs without compromising the tumor coverage. In this study we will compare the PTV coverage, conformity index and doses received by the OARs (urinary bladder, rectum, bowel bag, bilateral head of femur) by all the three techniques namely 3DCRT, IMRT and VMAT for carcinoma cervix patients undergoing concurrent Chemoradiotherapy (CRT) at our institution and further implement the results in our clinical practice. Material and Methods: Forty-five of biopsy-proven carcinoma cervix in stage IIA to IIIB were taken up for the study. Following imaging, contouring was carried out using the principal clinical findings and conventional RTOG recommendations. Dose prescription to the cervix was 50 Gy in 25 fraction and planned with all three modalities, 3DCRT, IMRT and VMAT. The patient was treated with the 3DCRT plan and the IMRT and VMAT plans were made for dosimetric purpose only. Results: Quantitative dose evaluation performed of three techniques V40, V45, V50, Dmean for Bladder and Rectum, Dmean and D100 for Femur, V30, V40, D195 CC, Dmean for Bowel. Results show that VMAT plan is preferable than IMRT for sparing Bladder and rectum. Conclusion: IMRT and VMAT both could be advocated for practice was tumor coverage was almost similar in both of them and decision could be made on patient specific logistics.","PeriodicalId":92329,"journal":{"name":"Annals of radiation therapy and oncology","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73989501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Single-Institution Analysis of Thymic Carcinoma Treated with Multi-Modality Therapy.","authors":"Imran H Mohiuddin,&nbsp;Muhammad Furqan,&nbsp;Gerald Clamon,&nbsp;John Keech,&nbsp;Carryn Anderson,&nbsp;Mark C Smith,&nbsp;John M Buatti,&nbsp;Bryan G Allen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Purpose: </strong>Review of our experience in treating thymic carcinoma patients using a combination of surgery, chemotherapy and radiation therapy.</p><p><strong>Methods: </strong>An institutional review of thymic carcinoma patients treated between 2007 and 2014 was performed analyzing clinical characteristics, treatment intent, surgical margin status, and radiation treatment dose. Survival curves were generated using the Kaplan-Meier method.</p><p><strong>Results: </strong>Nine individuals were treated for newly diagnosed thymic carcinoma. Three patients had unresectable disease at presentation; two of these were treated with definitive chemoradiation therapy while another received neoadjuvant chemotherapy. Seven subjects underwent surgical resection (one after neoadjuvant chemotherapy) with pathological staging ranging from IIa - IVb disease. Patients were planned for adjuvant radiotherapy followed by chemotherapy; however, one developed liver metastases prior to initiating radiotherapy and was therefore treated with palliative chemotherapy alone. A second patient was non-compliant with radiation treatments and was considered as treated with palliative chemotherapy alone. Of the seven patients who completed definitive treatment, median time to progression and overall survival has yet to be reached. Only one of these patients developed progressive disease 10 months after completing treatment and eventually succumbed to disease 41 months after completing definitive therapy. With a median follow up of 30 months, two year overall survival is 67% for all patients.</p><p><strong>Conclusion: </strong>Resection with an emphasis on best possible oncologic margins, followed by radiation and chemotherapy remains an effective treatment strategy for advanced stage thymic carcinoma. In patients who present with unresectable tumors, neoadjuvant chemotherapy or definitive chemoradiation therapy may also be considered as viable treatment strategies.</p>","PeriodicalId":92329,"journal":{"name":"Annals of radiation therapy and oncology","volume":"1 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36432291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}